guest ::
| Home > Publications database > Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes. > print |
| Home > Publications database > Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes. > print |
| 001 | 287441 | ||
| 005 | 20250814110933.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ebiom.2024.104977 |2 doi |
| 024 | 7 | _ | |a pmid:38290287 |2 pmid |
| 024 | 7 | _ | |a altmetric:158884791 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00244 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bull, Caroline J |b 0 |
| 245 | _ | _ | |a Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1706708406_24337 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Type 2 diabetes is associated with higher risk of several cancer types. However, the biological intermediates driving this relationship are not fully understood. As novel interventions for treating and managing type 2 diabetes become increasingly available, whether they also disrupt the pathways leading to increased cancer risk is currently unknown. We investigated the effect of a type 2 diabetes intervention, in the form of intentional weight loss, on circulating proteins associated with cancer risk to gain insight into potential mechanisms linking type 2 diabetes and adiposity with cancer development.Fasting serum samples from participants with diabetes enrolled in the Diabetes Remission Clinical Trial (DiRECT) receiving the Counterweight-Plus weight-loss programme (intervention, N = 117, mean weight-loss 10 kg, 46% diabetes remission) or best-practice care by guidelines (control, N = 143, mean weight-loss 1 kg, 4% diabetes remission) were subject to proteomic analysis using the Olink Oncology-II platform (48% of participants were female; 52% male). To identify proteins which may be altered by the weight-loss intervention, the difference in protein levels between groups at baseline and 1 year was examined using linear regression. Mendelian randomization (MR) was performed to extend these results to evaluate cancer risk and elucidate possible biological mechanisms linking type 2 diabetes and cancer development. MR analyses were conducted using independent datasets, including large cancer meta-analyses, UK Biobank, and FinnGen, to estimate potential causal relationships between proteins modified during intentional weight loss and the risk of colorectal, breast, endometrial, gallbladder, liver, and pancreatic cancers.Nine proteins were modified by the intervention: glycoprotein Nmb; furin; Wnt inhibitory factor 1; toll-like receptor 3; pancreatic prohormone; erb-b2 receptor tyrosine kinase 2; hepatocyte growth factor; endothelial cell specific molecule 1 and Ret proto-oncogene (Holm corrected P-value <0.05). Mendelian randomization analyses indicated a causal relationship between predicted circulating furin and glycoprotein Nmb on breast cancer risk (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.67-0.99, P-value = 0.03; and OR = 0.88, 95% CI = 0.78-0.99, P-value = 0.04 respectively), though these results were not supported in sensitivity analyses examining violations of MR assumptions.Intentional weight loss among individuals with recently diagnosed diabetes may modify levels of cancer-related proteins in serum. Further evaluation of the proteins identified in this analysis could reveal molecular pathways that mediate the effect of adiposity and type 2 diabetes on cancer risk.The main sources of funding for this work were Diabetes UK, Cancer Research UK, World Cancer Research Fund, and Wellcome. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer |2 Other |
| 650 | _ | 7 | |a DiRECT |2 Other |
| 650 | _ | 7 | |a Diabetes |2 Other |
| 650 | _ | 7 | |a Mendelian randomization |2 Other |
| 650 | _ | 7 | |a Obesity |2 Other |
| 650 | _ | 7 | |a Weight loss |2 Other |
| 700 | 1 | _ | |a Hazelwood, Emma |b 1 |
| 700 | 1 | _ | |a Legge, Danny N |b 2 |
| 700 | 1 | _ | |a Corbin, Laura J |b 3 |
| 700 | 1 | _ | |a Richardson, Tom G |b 4 |
| 700 | 1 | _ | |a Lee, Matthew |b 5 |
| 700 | 1 | _ | |a Yarmolinsky, James |b 6 |
| 700 | 1 | _ | |a Smith-Byrne, Karl |b 7 |
| 700 | 1 | _ | |a Hughes, David A |b 8 |
| 700 | 1 | _ | |a Johansson, Mattias |b 9 |
| 700 | 1 | _ | |a Peters, Ulrike |b 10 |
| 700 | 1 | _ | |a Berndt, Sonja I |b 11 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 12 |u dkfz |
| 700 | 1 | _ | |a Burnett-Hartman, Andrea |b 13 |
| 700 | 1 | _ | |a Cheng, Iona |b 14 |
| 700 | 1 | _ | |a Kweon, Sun-Seog |b 15 |
| 700 | 1 | _ | |a Le Marchand, Loic |b 16 |
| 700 | 1 | _ | |a Li, Li |b 17 |
| 700 | 1 | _ | |a Newcomb, Polly A |b 18 |
| 700 | 1 | _ | |a Pearlman, Rachel |b 19 |
| 700 | 1 | _ | |a McConnachie, Alex |b 20 |
| 700 | 1 | _ | |a Welsh, Paul |b 21 |
| 700 | 1 | _ | |a Taylor, Roy |b 22 |
| 700 | 1 | _ | |a Lean, Mike E J |b 23 |
| 700 | 1 | _ | |a Sattar, Naveed |b 24 |
| 700 | 1 | _ | |a Murphy, Neil |b 25 |
| 700 | 1 | _ | |a Gunter, Marc J |b 26 |
| 700 | 1 | _ | |a Timpson, Nicholas J |b 27 |
| 700 | 1 | _ | |a Vincent, Emma E |b 28 |
| 773 | _ | _ | |a 10.1016/j.ebiom.2024.104977 |g Vol. 100, p. 104977 - |0 PERI:(DE-600)2799017-5 |p 104977 |t EBioMedicine |v 100 |y 2024 |x 2352-3964 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/287441/files/1-s2.0-S2352396424000124-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/287441/files/1-s2.0-S2352396424000124-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:287441 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EBIOMEDICINE : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-26 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b EBIOMEDICINE : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-26 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-26 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|